Recombinant human prourokinase is comparable with alteplase in treatment of acute ischemic stroke (PROST)

Clinical Question

Is recombinant human prourokinase as effective as alteplase in the treatment of acute ischemic stroke?

Bottom line

In this industry-sponsored, Phase III trial, rhPro-UK was shown to be noninferior to alteplase in the treatment of acute ischemic stroke with a similar rate of symptomatic intracranial bleeding and a significantly decreased risk of systemic bleeding. It is easier to dose (standardized, non–weight-based dosing) and faster to administer (30 minutes vs 1 hour) than alteplase. The authors also note that, in China, this drug is half the price of alteplase (US$787 vs US$1577). 1b

Study design: Randomized controlled trial (nonblinded)

Funding: Industry

Setting: Inpatient (any location) with outpatient follow-up

Reviewer

Nita Shrikant Kulkarni, MD
Assistant Professor in Hospital Medicine
Northwestern University
Chicago, IL


Discuss this POEM


Comments

ARUP KUMAR DHARA

Impact assessment

Excellent

Bertus Johannes Reitsma

results

have these clinical results been confirmed in other geographies other than China ?

Anonymous

RECOMBINANT HUMAN POURAKINASE AND ANTIPLATELETS

GOOD TO KNOW

Anonymous

Excellent news

Great a less expensive recombinant product is now available